Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer Attending the Tikur Anbessa Specialized Hospital, Addis Ababa Ethiopia, 2019: A Cross-sectional Study

References

• WeinerCM, MathewosA, AddissieA, et al. Characteristics and follow-up of metastatic breast cancer in Ethiopia: a cohort study of 573 women. Breast. 2018;42:23–30.30149234
   PubMed Web of Science ®Google Scholar
• Indrojit RoyM. Breast Carcinoma in Uganda. Arch Pathol Lab Med. 2011;135.21204720
   PubMed Web of Science ®Google Scholar
• TimotewosG, SolomonA, MathewosA, et al. First data from a population based cancer registry in Ethiopia. Cancer Epidemiol. 2018;53:93–98.29414637
   PubMed Web of Science ®Google Scholar
• Eber-SchulzP, TarikuW, ReiboldC, et al. Survival of breast cancer patients in rural Ethiopia. Breast Cancer Res Treat. 2018;170(1):111–118.29479644
   PubMed Web of Science ®Google Scholar
• KinghamTP, AlatiseOI, VanderpuyeV, et al. Treatment of cancer in sub-Saharan Africa. Lancet Oncol. 2013;14(4):e158–e67.23561747
   PubMed Web of Science ®Google Scholar
• CondorelliR, Vaz-LuisI. Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Rev Anticancer Ther. 2018;18(11):1101–1112.30188738
   PubMed Web of Science ®Google Scholar
• BursonAM, SolimanAS, NgomaTA, et al. Clinical and epidemiologic profile of breast cancer in Tanzania. Breast Dis. 2010;31(1):33–41.21109721
   PubMedGoogle Scholar
• WataDE, OsanjoGO, OlukaM, GuantaiAN. Predictors of breast cancer treatment outcomes in Kenyan women. African J Pharmacol Ther. 2013;2(4):109–115.
   Google Scholar
• CondorelliR, Vaz-LuisI. Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Rev Anticancer Ther. 2018;18(11):1101.30188738
   PubMed Web of Science ®Google Scholar
• BrettJ, BoultonM, FenlonD, et al. Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence. Patient Prefer Adherence. 2018;12:291.29497284
   PubMed Web of Science ®Google Scholar
• FariasAJ, HansenRN, ZeliadtSB, OrnelasIJ, LiCI, ThompsonB. Factors associated with adherence to adjuvant endocrine therapy among privately insured and newly diagnosed breast cancer patients: a quantile regression analysis. J Managed Care Specialty Pharmacy. 2016;22(8):969–978.
   Web of Science ®Google Scholar
• LambertLK, BalneavesLG, HowardAF, GotayCC. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review. Breast Cancer Res Treat. 2018;1–19.
   Web of Science ®Google Scholar
• ChlebowskiRT. Adherence to oral endocrine therapy for breast cancer: a nursing perspective. Clin J Oncol Nursing. 2008.
   Web of Science ®Google Scholar
• IacorossiL, GambalungaF, FabiA, et al. Adherence to hormone therapy in women with breast cancer: a quantitative study. Prof Inferm. 2016;69:2.
   Google Scholar
• ChlebowskiRT, GellerML. Adherence to endocrine therapy for breast cancer. Oncology. 2006;71(1–2):1–9.17344666
   PubMed Web of Science ®Google Scholar
• LamWY, FrescoP. Medication adherence measures: an overview. Biomed Res Int. 2015;2015:217047.26539470
   PubMed Web of Science ®Google Scholar
• LambertLK, BalneavesLG, HowardAF, GotayCC. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review. Breast Cancer Res Treat. 2018;167(3):615–633.29110151
   PubMed Web of Science ®Google Scholar
• SawesiS, CarpenterJS, JonesJ. Reasons for nonadherence to tamoxifen and aromatase inhibitors for the treatment of breast cancer: a literature review. Clin J Oncol Nurs. 2014;18(3):E50–7.24867124
   PubMedGoogle Scholar
• TouchetteDR, ShapiroNL. Medication compliance, adherence, and persistence: current status of behavioral and educational interventions to improve outcomes. J Manag Care Pharm. 2008;14(6):S2–S10.
   PubMed Web of Science ®Google Scholar
• WickershamK, SereikaSM, BenderCM. Pretreatment predictors of short-term nonadherence to oral hormonal therapy for women with breast cancer. Nurs Res. 2013;62(4):243.23817282
   PubMed Web of Science ®Google Scholar
• OguntolaAS, AdeotiML, AkanbiO. Non-adherence to the use of tamoxifen in the first year by the breast cancer patients in an African population. East Cent Afr j Surg. 2011;16(1). .
   Google Scholar
• Group EBCTC. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–1717.15894097
   PubMed Web of Science ®Google Scholar
• FariasAJ, HansenRN, ZeliadtSB, OrnelasIJ, LiCI, ThompsonB. Factors associated with adherence to adjuvant endocrine therapy among privately insured and newly diagnosed breast cancer patients: a quantile regression analysis. J Managed Care Specialty Pharmacy. 2016;22(8):969–978.
   Web of Science ®Google Scholar
• HuiartL, BardouV, GiorgiR. L’adhésion thérapeutique aux traitements oraux: enjeux en oncologie-l’exemple du cancer du sein. Bull Cancer. 2013;100(10):1007–1015.24113516
   PubMed Web of Science ®Google Scholar
• AliEE, CheungKL, LeeCP, LeowJL, YapKY-L, ChewL. Prevalence and determinants of adherence to oral adjuvant endocrine therapy among breast cancer patients in Singapore. Asia-Pacific j Oncol Nursing. 2017;4(4):283.
   Web of Science ®Google Scholar
• AnyanwuSN, EgwuonwuOA, IhekwoabaEC. Acceptance and adherence to treatment among breast cancer patients in Eastern Nigeria. Breast. 2011;20:S51–S3.21295480
   PubMed Web of Science ®Google Scholar
• LiuY, MalinJL, DiamantAL, ThindA, MalyRC. Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider–patient communication. Breast Cancer Res Treat. 2013;137(3):829–836.23263740
   PubMed Web of Science ®Google Scholar
• MurphyCC, BartholomewLK, CarpentierMY, BluethmannSM, VernonSW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134(2):459–478.22689091
   PubMed Web of Science ®Google Scholar
• WheelerSB, RobertsMC, BloomD, et al. Oncology providers’ perspectives on endocrine therapy prescribing and management. Patient Prefer Adherence. 2016;10:2007.27757021
   PubMed Web of Science ®Google Scholar
• BrettJ, BoultonM, FenlonD, et al. Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence. Patient Prefer Adherence. 2018;12:291–300.29497284
   PubMed Web of Science ®Google Scholar
• OsterbergL, BlaschkeT. Adherence to medication. N Eng j Med. 2005;353(5):487–497.
   PubMed Web of Science ®Google Scholar
• BritoC, PortelaMC, de VasconcellosMTL. Adherence to hormone therapy among women with breast cancer. BMC Cancer. 2014;14(1):397.24893670
   PubMed Web of Science ®Google Scholar
• WulaningsihW, GarmoH, AhlgrenJ, et al. Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity. Breast Cancer Res Treat. 2018;172(1):167–177.30030708
   PubMed Web of Science ®Google Scholar
• HershmanDL, ShaoT, KushiLH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529–537.20803066
   PubMed Web of Science ®Google Scholar
• KroenkeCH, HershmanDL, GomezSL, et al. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system. Breast Cancer Res Treat. 2018;1–9.
   Web of Science ®Google Scholar
• DoggrellSA. Adherence to oral endocrine therapy in women with breast cancer: a mixed method study. Imperial j Interdisciplinary Res. 2016;2(8).
   Google Scholar
• QuinnEM, FlemingC, O’SullivanMJ. Endocrine therapy adherence: a cross-sectional study of factors affecting adherence and discontinuation of therapy. Ir J Med Sci. 2016;185(2):383–392.25971465
   PubMed Web of Science ®Google Scholar
• GaoP, YouL, WuD, et al. Adherence to endocrine therapy among Chinese patients with breast cancer: current status and recommendations for improvement. Patient Prefer Adherence. 2018;12:887–897.29872274
   PubMed Web of Science ®Google Scholar
• PhilipovskiyA, CampbellA, HeydarianR, et al. Adherence to Adjuvant aromatase inhibitor therapy among postmenopausal Hispanic/Latino women with breast cancer. Anticancer Res. 2020;40(2):857–864.32014929
   PubMed Web of Science ®Google Scholar
• LundgrenC, LindmanH, RolanderB, EkholmM. Good adherence to adjuvant endocrine therapy in early breast cancer–a population-based study based on the Swedish Prescribed Drug Register. Acta Oncologica. 2018;1–6.29297250
   PubMed Web of Science ®Google Scholar
• HeineySP, TrumanS, BabatundeOA, et al. Racial and geographic disparities in endocrine therapy adherence among younger breast cancer survivors. Am J Clin Oncol. 2020;43(7):504–509.32251120
   PubMed Web of Science ®Google Scholar
• KroenkeCH, HershmanDL, GomezSL, et al. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system. Breast Cancer Res Treat. 2018;170(3):623–631.29671113
   PubMed Web of Science ®Google Scholar
• MoonZ, Moss-MorrisR, HunterMS, CarlisleS, HughesLD. Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Prefer Adherence. 2017;11:305–322.28260867
   PubMed Web of Science ®Google Scholar
• ToledoG, OchoaCY, FariasAJ. Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors. Supportive Care Cancer. 2020;28(1):271–278.
   Web of Science ®Google Scholar
• LiuY, MalinJL, DiamantAL, ThindA, MalyRC. Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat. 2013;137(3):829–836.23263740
   PubMed Web of Science ®Google Scholar
• RobinsonB, DijkstraB, DaveyV, TomlinsonS, FramptonC. Adherence to adjuvant endocrine therapy in Christchurch women with early breast cancer. Clin oncol. 2018;30(1):e9–e15.
   Web of Science ®Google Scholar
• GanzPA, CecchiniRS, JulianTB, et al. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, Phase 3 clinical trial. Lancet. 2016;387(10021):857–865.26686960
   PubMed Web of Science ®Google Scholar
• CheungWY, LaiEC, RuanJY, ChangJT, SetoguchiS. Comparative adherence to oral hormonal agents in older women with breast cancer. Breast Cancer Res Treat. 2015;152(2):419–427.26070268
   PubMed Web of Science ®Google Scholar
• ZhaoH, HeiN, WuY, et al. Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ. Cancer. 2017;123(6):940–947.27780311
   PubMed Web of Science ®Google Scholar